Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Department of Justice
Chubb
Mallinckrodt
Cerilliant
Medtronic
McKesson
Boehringer Ingelheim
Citi
Julphar

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206619

« Back to Dashboard
NDA 206619 describes VIEKIRA PAK (COPACKAGED), which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug. Additional details are available on the VIEKIRA PAK (COPACKAGED) profile page.

The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.

Summary for NDA: 206619

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:18
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 206619

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL 206619 NDA AbbVie Inc. 0074-3093 0074-3093-01 1 DOSE PACK in 1 CARTON (0074-3093-01) > 1 KIT in 1 DOSE PACK
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL 206619 NDA AbbVie Inc. 0074-3093 0074-3093-28 4 CARTON in 1 CARTON (0074-3093-28) > 7 DOSE PACK in 1 CARTON > 1 KIT in 1 DOSE PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, TABLET;ORALStrengthEQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG
Approval Date:Dec 19, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 22, 2019
Regulatory Exclusivity Use:DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Jul 19, 2019Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 206619

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Federal Trade Commission
McKesson
UBS
Dow
Cipla
Novartis
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot